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Copyright © 2011 JCBN 2011 This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unre- stricted use, distribution, and reproduction in any medium, pro- vided the original work is properly cited. The cholesterol ozonolysis products secosterol A and its aldoliza 
tion product secosterol B were recently detected in human athero 
sclerotic tissues and brain specimens, and have been postulated to
play pivotal roles in the pathogenesis of atherosclerosis and
neurodegenerative diseases. We examined several oxidized
cholesterol metabolites including secosterol A, secosterol B, 25 
hydroxycholesterol, 5β,6β epoxycholesterol and 7 ketocholesterol
for their effects on the activities of three nitric oxide synthases. In
contrast to other oxidized metabolites, secosterol A was found to
be a potent inhibitor against the neuronal  and endothelial type,
but not the inducible type nitric oxide synthase, with IC50 values
of 22 ± 1 and 50 ± 5 μM, respectively. The calmodulin binding
regions of the neuronal  and endothelial nitric oxide synthases
contain lysine residues which are not present in the inducible type
nitric oxide synthase. Secosterol A modifies proteins through the
formation of a Schiff base with the lysine epsilon amino group. It
is possible that secosterol A modifies lysine residues of constitu 
tive nitric oxide synthases, leading to the inhibition of enzymatic
activities. As nitric oxide is a critical signaling molecule in vascular
function and in long term potentiation, its reduced production
through inhibition of constitutive nitric oxide synthases by
secosterol A may contribute to the development of atherosclerosis
and memory impairment in particular neurodegenerative diseases.
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Introduction Oxidized cholesterol metabolites, 3β-hydroxy-5-oxo-5,6-
secocholestan-6-al (secosterol-A) and its aldolization
product, 3β-hydroxy-5β-hydroxy-B-norcholestane-6β-carboxal-
dehyde (secosterol-B), have recently been detected in human
atherosclerotic tissues(1) and in human brain specimens (Fig. 1).(2,3)
Secosterol-A was previously reported to form through the
cleavage of the Δ5,6 double bond of cholesterol by only ozone
among the various reactive oxidants including singlet oxygen
(1O2), superoxide anion, hydroxyl radical and ozone.(4–6) On the
basis of these previous studies, Wentworth and co-workers
proposed that secosterol-A is formed in atherosclerotic plaques by
oxidation of cholesterol with ozone, which is generated in the
presence of leukocytes and immunoglobulins, and is converted to
secosterol-B by an aldolization reaction.(1) Ozone could be formed
by activated neutrophils through antibody (immunoglobulin)-
catalyzed oxidation of water with 1O2, which is generated from the
reaction of H2O2 with HOCl.(7,8) The concentration of secosterol-A
was shown to increase significantly upon activation with phorbol
myristate acetate (PMA) in atherosclerotic lesions collected from
patients.(1) Brinkhorst et al.(9) and Uemi et al.(10) recently reported
that both secosterol-A and -B are directly formed via Hock
cleavage of cholesterol 5α-hydroperoxide, which is formed from
the reaction of cholesterol with 1O2. However, secosterol-B was
formed more easily(9,10) from 5α-hydroperoxide under acidic
conditions in organic solvents, whereas secosterol-A was either
not formed at all or was a minor component in the aqueous
buffer.(11) We also reported that secosterols are formed by the
reaction of cholesterol with human myeloperoxidase (MPO) in
the presence of its substrates H2O2 and Cl−.(12) More recently we
found that neutrophil-like differentiated human leukemia HL-60
(nHL-60) cells activated with PMA produced significantly increased
levels of secosterol-A and its aldehyde-oxidation product. This
secosterol-A increase was reduced in the culture of PMA-activated
nHL-60 cells containing several ROS inhibitors and scavengers or
in a culture of PMA-activated neutrophils isolated from MPO-
deficient mice.(13) These results suggest that secosterol-A is formed
by an ozone-like oxidant generated with PMA-activated neutro-
phils through an MPO-dependent mechanism. Although the exact
mechanism for the formation of secosterols in vivo remains
unresolved, these compounds have been reported to be strongly
cytotoxic against various types of cells.(1,14–16) They also have the
ability to covalently modify the amyloid-β peptide, α-synuclein
and apolipoprotein C-II, accelerating their amyloidogenesis and
fibrilization  in vitro.(2,3,17) Amyloidogenesis and/or fibrilization
represent defining features of Alzheimer’s, Parkinson’s and
related amyloid diseases as well as atherosclerosis.(3,17,18) These
results indicate that the formation of secosterols in inflamed tissues
may contribute to the increased risks of a variety of diseases
including atherosclerosis and neurodegenerative diseases such as
sporadic Alzheimer’s disease in subjects with hypercholesterolemia
and inflammation.
Nitric oxide (NO), identified as an endothelium-derived
relaxing factor (EDRF), is a critical signaling molecule in vascular
function and homeostasis in mammals.(19) NO is formed during the
oxidation of L-arginine to L-citrulline, a reaction catalyzed by NO
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synthases (NOSs, EC 1.14.13.39). Three NOS isoforms have been
characterized and cloned: neuronal NOS (nNOS; type I), inducible
NOS (iNOS; type II), and endothelial NOS (eNOS; type III).(20)
Constitutive NOSs (eNOS and nNOS) are associated with the
regulation of vascular tone in blood vessels and neurotransmission
in the central and peripheral nervous tissues. In the immune
system, inflammatory cytokines stimulate iNOS expression in
macrophages and other cell types to provide defense against
pathogens. Prolonged production of excess amounts of NO may
damage normal tissues, thereby contributing to the development
of chronic inflammatory diseases including atherosclerosis and
neurodegenerative diseases.
Vascular diseases associated with hypercholesterolemia, diabetes
and hypertension are characterized by endothelial dysfunction and
reduced endothelium-mediated vasodilation. The inactivation and
impaired generation of NO by reactive oxygen species play an
important role in these disease states. For these reasons, we have
studied the effects of several oxidized cholesterol metabolites on
the activities of three isoforms of NOS in vitro. These included
the metabolites 25-hydroxycholesterol, 5β,6β-epoxycholesterol,
7-ketocholesterol, secosterol-A and secosterol-B (Fig. 1). 25-
Hydroxycholesterol is produced enzymatically by cholesterol
25-hydroxylase and acts as a potent inhibitor of cholesterol
biosynthesis in different cell types.(21,22) 5β,6β-Epoxycholesterol
has been studied as a product of cholesterol autooxidation and lipid
peroxidation(23) and has been shown to cause cytotoxicity in in
vitro systems.(24,25) 7-Ketocholesterol (3β-hydroxy-5-cholesten-7-
one) is also a cholesterol autooxidation product and shows delete-
rious proinflammatory and pro-apoptotic effects in vitro.(26,27) In
the present study, the primary ozonolysis product of cholesterol,
secosterol-A, was found to be a potent inhibitor of both nNOS and
eNOS, but not of iNOS. We discuss possible pathophysiological
roles of oxidized cholesterol metabolites in the development of
atherosclerosis and neurodegenerative diseases in relation to the
impairment of NO production mediated by inhibition of nNOS
and eNOS with secosterol-A.
Materials and Methods
Materials. Secosterol-A and -B were synthesized according
to Wentworth et al.(1) L-Arginine, nicotinamide adenine dinucleotide
phosphate reduced form (NADPH), flavin adenine dinucleotide
(FAD), flavin mononucleotide (FMN), (6R)-5,6,7,8-tetrahydro-
biopterin (BH4), recombinant eNOS (from bovine), iNOS (from
mouse macrophages), and Dowex® AG50W-X8 cation-exchange
resin (mesh size, 100–200) were all purchased from Sigma Chem.
(St. Louis, MO). Ultima Gold XR scintillation liquid was from
PerkinElmer (Shelton, CA). Recombinant nNOS (from rat) was
obtained from Cayman Chem. All other chemicals were obtained
from Wako Pure Chem. Ind., Osaka, Japan.
Assay for NOSs activities. The NOS activities were deter-
mined by monitoring the conversion of L-[14C(U)]-arginine
(Moravek, Brea, CA) to L-[14C(U)]-citrulline as previously
described.(28) Recombinant enzymes of three isoforms of NOS
(specific activity: eNOS 0.03, nNOS 2.9, iNOS 0.62 units/mg
protein) (10 μl) were added to a reaction mixture (final volume of
100 μl) consisting of 50 mM HEPES buffer (pH 7.4), 1 mM
NADPH, 4 μM FAD, 4 μM FMN, 10 μM BH4, 1 mg/L (60 μM)
calmodulin (CaM), 2.5 mM CaCl2, 50 μM L-arginine, 0.5 μCi/ml
of L-[14C(U)]-arginine (specific activity: 8.14–11.1 GBq/mmol)
and varying concentrations of the test compound. After incubation
for 30 min at 37°C, the reactions were terminated by the addition
of 0.5 ml of 20 mM HEPES (pH 5.5) containing 2 mM EDTA
and 2 mM EGTA. Samples were passed through a 1 ml column
of Dowex AG50W-X8 (Na+-form) to remove unconverted L-
[14C(U)]-arginine. L-[14C(U)]-Citrulline was eluted twice with
1 ml of distilled water, and the eluted fractions mixed with 10 ml
of cocktail (Ultima Gold XR) were quantified using a liquid
scintillation counter. A reaction mixture containing L-[14C(U)]-
arginine without the enzyme was incubated as a control to
determine background counts. The effects of oxidized cholesterol
metabolites on the NOSs activities were examined in the presence
and absence of the test compounds at various concentrations,
which were prepared in 5% ethanol and a 10 μl aliquot was added
into the reaction mixture.
Initial rates of citrulline formation were obtained by linear
leastsquares data fitting of actual experimental data. Apparent Km
and Vmax values at each inhibitor concentration were obtained from
nonlinear regression fitting using the Michaelis-Menten equation.
Ki and Kiʹ were obtained from the X-axis intercepts of plots of
measured Km/Vmax and 1/Vmax vs inhibitor concentration, respec-
tively.
Statistical analysis. All experiments were repeated 3–8 times.
Representative results are shown as means ± standard deviations
(SD). For statistical comparison between two groups, an unpaired
t test was used.




Effects of cholesterol and various oxidized cholesterol
metabolites on the activities of three NOS isoforms.
Cholesterol and its oxidized metabolites including 25-hydroxy-
cholesterol, 5β,6β-epoxycholesterol, 7-ketocholesterol, secosterol-
A and secosterol-B were examined for their effects on the
activities of three NOS isoforms in vitro. As shown in Fig. 2 A and
B, only secosterol-A exhibited potent inhibitory effects on nNOS
and eNOS activities in a concentration-dependent manner, with
IC50 values of 22 ± 1 and 50 ± 5 μM, respectively. Interestingly,
secosterol-A at the same tested concentrations (1–100 μM) did not
affect the iNOS activity (Fig. 2C). Cholesterol and other oxidized
cholesterol metabolites exhibited no inhibitory effects on the
activities of three NOS isoforms even at the highest concentration
(100 μM) (Fig. 2 A–C).
Kinetics for substrate dependent constitutive NOS by
secosterol A. To elucidate the mechanism for inhibition of
constitutive NOSs (nNOS and eNOS) by secosterol-A, a series
of enzyme assays were carried out in the presence of varying
concentrations of its substrate L-arginine and the inhibitor
secosterol-A. Depending on the secosterol-A concentration, the
presence of an excess amount of L-arginine only partially recovered
the activities of nNOS and eNOS inhibited by secosterol-A
(Fig. 3A and 4A). Double reciprocal (Lineweaver-Burke) plots of
constitutive NOSs activities vs L-arginine concentrations in the
absence and presence of varying amounts of secosterol-A are
shown in Fig. 3B and 4B. The kinetics parameters obtained from
these plots are shown in Table 1. The pattern of secosterol-A-
mediated inhibition of the rat nNOS activity indicates that the
inhibition was noncompetitive or a mixed-type. Here, a Ki value
of 10 μM for the catalytic site and a Kiʹ value of 1 μM for the
allosteric site were observed. These results suggest that secosterol-
A can bind more easily with the enzyme-L-arginine complex than
the apo-enzyme. The inhibition of the bovine eNOS activity by
secosterol-A followed a similar pattern as that of the rat nNOS
activity (Fig. 4B), with the Ki and Kiʹ values being 50 and
23.3 μM, respectively.
The effects of CaM and BH4 concentrations on the secos 
terol A mediated inhibition of constitutive NOSs activities.
We next examined the possibility whether secosterol-A interfered
with the binding of cofactors CaM and BH4 to the constitutive
Fig. 2. Effects of oxidized cholesterol metabolites on the enzymatic activities of three isoforms of NOSs, (A) nNOS, (B) eNOS and (C) iNOS. A
reaction mixture containing a recombinant NOS, necessary cofactors, 50 μM L arginine (including L [14C(U)] arginine) and a test compound at the
indicated concentration was incubated for 30 min at 37°C. Results are shown as the means ± SD normalized to a value of 100% for the control (the
absence of compounds) (n = 3–6). Significantly different when compared with the control, *p<0.01. cholesterol (×), 25 hydroxycholesterol (◆),
5β,6β epoxycholesterol (■), 7 ketocholesterol (▲), secosterol A (●) and secosterol B (○).
Fig. 3. Effect of secosterol A on L arginine dependent nNOS activity.
(A) nNOS activity both in the absence (○) and presence of 20 (●), 30
(◆) or 40 μM (×) secosterol A; (B) A double reciprocal (Lineweaver 
Burke) plot. J. Clin. Biochem. Nutr. | January 2012 | vol. 50 | no. 1 | 87
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NOSs. In the presence of 60 μM CaM, secosterol-A at 40 μM
concentration reduced the nNOS activity to 22% when compared
to the activity without secosterol-A. The addition of excess CaM
at 300 and 600 μM in the presence of 40 μM secosterol-A restored
the nNOS activity to 63 and 86%, respectively (Fig. 5A). On the
other hand, the addition of excess CaM did not restore the eNOS
activity inhibited by the presence of 100 μM secosterol-A
(Fig. 5A). In contrast, in the presence of 10 μM BH4, 40 and
100 μM secosterol-A significantly decreased the nNOS and eNOS
activities to 23 and 41% of the activities without secosterol-A,
respectively (Fig. 5B). The addition of 50 and 100 μM BH4 did not
restore the activities of constitute NOSs inhibited by secosterol-A
(Fig. 5B).
As Fig. 6A shows, the addition of excess amounts of CaM only
partially recovered the activity of nNOS in the presence of varying
concentrations of secosterol-A. Double reciprocal (Lineweaver-
Burke) plots of nNOS activities versus CaM concentrations in the
absence and presence of secosterol-A are shown in Fig. 6B. The
secosterol-A-mediated inhibition of rat nNOS activities was
noncompetitive or a mixed-type of inhibition, with a Ki value of
1 μM for the catalytic site and a Kiʹ of 30 μM for the allosteric
site. This observation suggests that secosterol-A binds more easily
with the apo-enzyme than the enzyme-CaM complex.
Fig. 4. Effect of secosterol A on L arginine dependent eNOS activity.
(A) eNOS activity both in the absence (○) and presence of 50 (●) or
100 μM (◆) secosterol A; (B) A double reciprocal (Lineweaver Burke)
plot.
Table 1. Kinetic parameters for the inhibition of constitutively active NOSs by secosterol A
Km(app)ʹ, Ki and Kiʹ were obtained based on the results in Fig. 3 and 4. Ki(app) for the catalytic site and Ki(app)ʹ for the allosteric site. Values of IC50 were
calculated from IC50 =1 0 (log(A/B)*(50–C)/(D–C)+log(B)). A and B represent the highest and lowest concentrations of an inhibitor, respectively. C and D represent
the % inhibition in the presence of B or A, respectively.
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Fig. 5. Effects of increased calmodulin (CaM) or BH4 concentrations on
constitutive NOSs inhibition by secosterol A. Addition of increasing con 
centrations of CaM (60–600 μM) (A) or BH4 (10–100 μM) (B) to the reac 
tion mixture containing nNOS (closed bars) or eNOS (open bars). nNOS
and eNOS activities were determined in the presence of secosterol A
(Seco A) at concentrations of 40 and 100 μM, respectively. Results are
shown as the means ± SD normalized to a value of 100% for the control
(the absence of secosterol A) (n = 3).  #significantly different (p<0.05)
when compared with the control (the absence of secosterol A). *signifi 
cantly different (p<0.05) when compared with the reaction in the




The present results show that although cholesterol and its
oxidized metabolites such as 25-hydroxycholesterol, 5β,6β-
epoxycholesterol, 7-ketocholesterol and secosterol-B do not affect
the enzymatic activities of NOSs, only secosterol-A at relatively
low concentrations strongly inhibits the enzymatic activities of
eNOS and nNOS, but not iNOS. This inhibition by secosterol-A
of rat nNOS activity was partially restored by the addition of
increased amounts of CaM, but not BH4. In contrast, the inhibition
by secosterol-A of bovine eNOS was not ameliorated by adding
increased amounts of CaM and BH4. These results suggest that
the binding sites of CaM, but not that of BH4, in nNOS may be
important for secosterol-A inhibitory activity. Further studies
are required to elucidate the mechanisms by which secosterol-A
inhibits only constitutive NOSs, but not inducible NOSs.
Although the exact mechanisms for the inhibition of constitutive
NOSs by secosterol-A is unresolved, it is likely that secosterol-A
interacts with eNOS and nNOS and modifies their conformations.
Previous studies(2,3) have shown that hydrophobic aldehydes,
including secosterol-A, modify proteins through the formation of
a Schiff base with the lysine epsilon-amino group or N-terminal
amino group. We compared the amino acid sequences of three
NOSs isoforms (bovine eNOS, rat nNOS and mouse iNOS)
(UniProtKB/Swiss-Prot P29473, P29476 and P29477, respec-
tively). There are 12 lysine residues which are present in both
eNOS and nNOS, but not in iNOS. Interestingly, four out of these
12 lysine residues in the rat nNOS (K717, K725, K732, K743) are
localized near or within the CaM-binding region (725–745) and
two (K751 and K754) are present in the BH4-binding region (750–
769). The same amino acid sequences are found in the bovine
eNOS (K488, K496, K499, K506, K518 and K521) near or within
the CaM- or BH4-binding regions, whereas these lysine residues
are replaced by other amino acids (Q496, R504, R510, F507, S529
and R532, respectively) in the mouse iNOS. We speculate that
secosterol-A reacts with one or more lysine residues in these
regions to modify their conformations, leading to the inhibition of
the binding of the cofactors, and thereby reducing the activities of
eNOS and nNOS. As these lysine residues are also well conserved
in human eNOS and nNOS (UniProtKB/Swiss-Prot P29474,
P29475), it is expected that secosterol-A may inhibit human
constitutive NOSs in a similar fashion as the bovine and rat
homologues. Further studies are needed to elucidate the inhibition
mechanisms of constitutive NOSs by secosterol-A, but not by
other cholesterol oxidized metabolites. Although there have been
no published studies concerning the comparison of the reactivity
with proteins among various oxysterols, our preliminary data
show that secosterol-A can react with proteins such as bovine
serum albumin to form the adduct more easily than secosterol-B
(unpublished data).
Multiple lines of investigation indicate that NO produced by
eNOS is atheroprotective and that NO deficiency is critically
involved in the pathogenesis of hypercholesterolemia-induced
vascular disease.(29) The eNOS protein has been shown to be
associated with caveolae as a result of myristoylation on the
glycine adjacent to the leading methionine and thiopalmitoylation
on the cysteine at positions 15 and 26.(30,31) Caveolae are special-
ized, lipid-ordered plasma membrane microdomains enriched in
cholesterol, glycosphingolipids, sphingomyelin, and lipid anchored
membrane proteins, and they contain a variety of signal-transduc-
tion molecules. Membrane cholesterol is essential for normal
caveolae function. The concentration of secosterol-A in the
atherosclerotic lesions of patients displaying an atherosclerosis
disease state have been reported to be in the range of 6.8 and
61.3 pmol/mg of plaque (7–60 μM). Significant amounts of
secosterol-A (up to 200 pmol/mg of plaque, ~200 μM) were also
found to be formed in atherosclerotic lesions upon activation
with PMA.(1) As the IC50 value for eNOS was 50 ± 5 μM, it is
possible that the secosterol-A formed in caveolae reacts directly
with the caveolae-associated eNOS to inhibit enzymatic activity.
The brain contains the highest levels of cholesterol in mammalian
organs. High levels of total cholesterol in serum have been shown
to be a risk factor in the pathology of the central nervous system
associated with the development of neurodegenerative diseases
such as Alzheimer’s disease and Parkinson’s disease.(32,33) Choles-
terol may be oxidized to generate secosterols during inflammation
and oxidative stress. Low levels of secosterol-A and -B have been
detected in human and rat brain samples at combined concentra-
tions of up to 400 pg/mg of wet brain (~1 μM concentration).
However, as these secosterols are very reactive, free forms may
disappear rapidly from the tissues by forming adducts with pro-
teins. Consequently, much higher concentrations of secosterols
may actually be continuously generated in inflamed tissues. On
the basis of these facts, it is plausible that nNOS in the brain could
also be inhibited by secosterol-A. As NO plays an important role
in long-term potentiation, a form of synaptic plasticity that is a
putative mechanism of memory formation in the hippocampus,
reduced NO production through inhibition of nNOS by secosterol-
A may contribute to impairment of memory during the develop-
ment of neurodegenerative diseases.
It is also interesting to note that secosterol-A did not affect the
enzyme activity of iNOS. Secosterol-A could be formed during
Fig. 6. Effect of secosterol A on CaM dependent nNOS activity. (A)
nNOS activity both in the absence (○) and presence of 25 (●), 30 (◆) or
40 μM (×) secosterol A; (B) A double reciprocal (Lineweaver Burke) plot. J. Clin. Biochem. Nutr. | January 2012 | vol. 50 | no. 1 | 89
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inflammation and oxidative stress under which iNOS may also be
expressed simultaneously. As both secosterol-A and excess NO
are cytotoxic, it is possible that both compounds may exert
detrimental effects against normal tissues and induce inflam-
mation-related tissue damage.
In conclusion, we have shown that the oxidized cholesterol
metabolite secosterol-A is a potent inhibitor of eNOS and nNOS,
but not iNOS in vitro. Since secosterol-A has been reported to be
present and/or formed in human atherosclerotic tissues and in
human brain specimens, is strongly cytotoxic against various
types of cells, and can covalently modify various proteins
including amyloid-β peptide and apolipoprotein, the impairment
of NO production mediated through inhibition of eNOS and nNOS
by secosterol-A may contribute to the development of athero-
sclerosis and particular neurodegenerative diseases.
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